

## REFERENCES

- [1] Griffith JD, Comeau L, Rosenfield S, Stansel RM, et al. Mammalian telomeres end in a large duplex loop. *Cell*. 1999 May 14;97(4):503-14.
- [2] André Olaussen K, Dubrana K, Domont J, Spano J.P, Sabatier L, Soria JC. Telomeres and telomerase as targets for anticancer drug development. *Critical Reviews in Oncology/Hematology*. 2006 ;57:191–214.
- [3] Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. *Nat Rev Cancer*. 2008 Jun;8(6):450-8.
- [4] Levy MZ, Allsopp RC, Futcher AB, Greider CW, Harley CB. Telomere end-replication problem and cell aging. *J. Mol. Biol*. 1992;225:951–60.
- [5] Baird DM, Britt-Compton B, Rowson J, Amso NN, Gregory L, Kipling D. Telomere instability in the male germline. *Hum. Mol. Genet*. 2006;15:45–51.
- [6] Graakjaer J, Pascoe L, Der-Sarkissian H, Thomas G, Kolvraa S, et al.. The relative lengths of individual telomeres are defined in the zygote and strictly maintained during life. *Aging Cell*. 2004;3:97–102.
- [7] Lansdorp PM, Verwoerd NP, van de Rijke FM, Dragowska V, Little MT, et al.. Heterogeneity in telomere length of human chromosomes. *Hum. Mol. Genet*. 1996;5:685–91.

- [8] Zijlmans JM, Martens UM, Poon SS, Raap AK, Tanke HJ, et al.. Telomeres in the mouse have large interchromosomal variations in the number of T2AG3 repeats. *Proc. Natl. Acad. Sci. USA.* 1997;94:7423–8.
- [9] Baird DM, Rowson J, Wynford-Thomas D, Kipling D. Extensive allelic variation and ultrashort telomeres in senescent human cells. *Nat. Genet.* 2003;33:203–7.
- [10] Der-Sarkissian H, Bacchetti S, Cazes L, Londono-Vallejo JA. The shortest telomeres drive karyotype evolution in transformed cells. *Oncogene.* 2004.;23:1221–8.
- [11] Britt-Compton B, Rowson J, Locke M, Mackenzie I, Kipling D, Baird DM. Structural stability and chromosome-specific telomere length is governed by cis-acting determinants in humans. *Hum. Mol.Genet.* 2006;15:725–33.
- [12] Graakjaer J, Bischoff C, Korsholm L, Holstebro S, Vach W, et al. The pattern of chromosomespecific variations in telomere length in humans is determined by inherited, telomere-near factors and is maintained throughout life. *Mech. Ageing Dev.* 2003;124:629–40.
- [13] Graakjaer J, Der-Sarkissian H, Schmitz A, Bayer J, Thomas G, et al.. Allele-specific relative telomere lengths are inherited. *Hum. Genet.* 2006;119:344–50.
- [14] Graakjaer J, Pascoe L, Der-Sarkissian H, Thomas G, Kolvraa S, et al.. The relative lengths of individual telomeres are defined in the zygote and strictly maintained during life. *Aging Cell.* 2004;3:97–102.

- [15] Riethman H, Ambrosini A, Castaneda C, Finklestein J, Hu XL, et al.. Mapping and initial analysis of human subtelomeric sequence assemblies. *Genome Res.* 2004;14:18–28.
- [16] Brown WR, MacKinnon PJ, Villasante A, Spurr N, Buckle VJ, Dobson MJ. Structure and polymorphism of human telomere-associated DNA. *Cell.* 1990;63:119–32.
- [17] Royle NJ, Hill MC, Jeffreys AJ. Isolation of telomere junction fragments by anchored polymerase chain reaction. *Proc. Biol. Sci.* 1992;247:57–67.
- [18] Ambrosini A, Paul S, Hu S, Riethman H. Human subtelomeric duplicon structure and organization. *Genome Biol.* 2007;8:151.
- [19] Riethman H.. Human Telomere Structure and Biology. *Annu. Rev. Genomics Hum. Genet.* 2008;9:1–19.
- [20] Granger M P, Wright W E, Shay J W. Telomerase in cancer and aging. *Critical Reviews in Oncology/Hematology.* 2002; 41:29–40.
- [21] Hiyama K. *Telomeres and Telomerase in Cancer.* 2 nd ed. Springer Publishers;2009.
- [22] Azzalin CM, Nergadze SG, Giulotto E. Human intrachromosomal telomeric-like repeats: sequence organization and mechanisms of origin. *Chromosoma.* 2001;110:75–82.
- [23] Cong Yu-S, Wright W E., and Shay J W. Human Telomerase and Its Regulation. *Microbiology and Molecular Biology Reviews,* Sept. 2002;66(3):407–425.

- [24] Shay JW and Wright W E. Telomerase therapeutics for cancer: challenges and new directions. *Nature Reviews Drug Discovery*. 2006 June;9:1-8.
- [25] Shay JW, Wright WE. Senescence and immortalization: role of telomeres and telomerase. *Carcinogenesis*. 2005; 26:867-874.
- [26] Wu C, Miloslavskaya I, Demontis S, Maestro R, Galaktionov K. Regulation of cellular response to oncogenic and oxidative stress by Seladin-1. *Nature*. 2004;432:640-645.
- [27] Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. *Nature*. 2005;436:720-724.
- [28] Collado M, Gil J, Efeyan A, Guerra C et al. Senescence in premalignant tumours. *Nature*. 2005;436:642.
- [29] Braig M, Lee S, Loddenkemper C, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. *Nature*. 2005;436:660-665.
- [30] Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. *Nature*. 2005;436:725-730.
- [31] Wu CH, van Riggelen J, Yetil A, Fan AC, et al.. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. *Proc Natl Acad Sci USA*. 2007;104:13028-33.
- [32] Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. *Nature*. 2007;445:656-660.

- [33] Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression *in vivo*. *Nature*. 2007;445:661-665.
- [34] Finkel T, Serrano M, Blasco MA. The common biology of cancer and ageing. *Nature*. 2007;448:767-774.
- [35] Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. *Cell*. 1997;90:785-95.
- [36] Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. *Science*. 1997;277:955-9.
- [37] Feng J, Funk WD, Wang SS, et al.. The RNA component of human telomerase. *Science*. 1995;269:1236-41.
- [38] Mitchell JR, Cheng J, Collins K. A box H/ACA small nucleolar RNA-like domain at the human telomerase RNA 3end. *Mol Cell Biol*. 1999;19:567-76.
- [39] Arai K, Masutomi K, Khurts S, et al. Two independent regions of human telomerase reverse transcriptase are important for its oligomerization and telomerase activity. *J Biol Chem*. 2002;277:8538-44.
- [40] Beattie TL, Zhou W, Robinson MO, Harrington L. Functional multimerization of the human telomerase reverse transcriptase. *Mol Cell Biol*. 2001;21:6151-60.
- [41] Wenz C, Enenkel B, Amacker M, et al. Human telomerase contains two cooperating telomerase RNA molecules. *EMBO J*. 2001;20:3526-34.

- [42] Beattie TL, Zhou W, Robinson MO, Harrington L. Reconstitution of human telomerase activity *in vitro*. *Curr Biol*. 1998;8:177–80.
- [43] Weinrich SL, Pruzan R, Ma L, et al. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTERT. *Nat Genet*. 1997;17:498–502.
- [44] Harrington L, McPhail T, Mar V, et al. A mammalian telomerase-associated protein. *Science*. 1997;275:973–7.
- [45] Harrington L, Zhou W, McPhail T, et al. Human telomerase contains evolutionarily conserved catalytic and structural subunits. *Genes Dev*. 1997;11:3109–15.
- [46] Holt SE, Aisner DL, Baur J, et al. Functional requirement of p23 and Hsp90 in telomerase complexes. *Genes Dev*. 1999;13:817–26.
- [47] Liu Y, Snow BE, Hande MP, et al. Telomerase-associated protein TEP1 is not essential for telomerase activity or telomere length maintenance *in vivo*. *Mol Cell Biol*. 2000;20:8178–84.
- [48] Le S, Sternglanz R, Greider CW. Identification of two RNA-binding proteins associated with human telomerase RNA. *Mol Biol Cell*. 2000;11:999–1010.
- [49] Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. *Nature*. 1999;402:551–555.
- [50] Autexier C. and Lue NF. The Structure and Function of Telomerase Reverse Transcriptase. *Annu. Rev. Biochem*. 2006;75:493–517.



- [51] Greenberg, R A., Allsopp RC, Chin L, Morin GB, and De RA. Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation. *Oncogene*. 1998;16:1723–30.
- [52] Meyerson, M, Counter CM, Eaton EN, Ellisen LW, et al.. hEST2, the putative human telomerase catalytic subunit gene, is upregulated in tumor cells and during immortalization. *Cell*. 1997;90:785–795.
- [53] Xu, D, Gruber A, Bjorkholm M, Peterson C, and Pisa P. Suppression of telomerase reverse transcriptase (hTERT) expression in differentiated HL-60 cells: regulatory mechanisms. *Br. J. Cancer*. 1999;80:1156–61.
- [54] Zhang W, Piatyszek MA, Kobayashi T, Estey E, et al.. Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. *Clin. Cancer Res*. 1996;2:799–803.
- [55] Hande, M. P., Balajee AS, and Natarajan AT. Induction of telomerase activity by UV-irradiation in Chinese hamster cells. *Oncogene*. 1997;15:1747-52.
- [56] Xu D, Erickson S, Szeps M, Gruber A, Sangfelt O, et al.. Interferon alpha downregulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. *Blood*. 2000;96:4313–18.
- [57] Kyo, S, Takakura M, Kanaya T, Zhuo W, Fujimoto K, et al.. Estrogen activates telomerase. *Cancer Res*. 1999;59:5917–21.
- [58] Misiti, S, Nanni S, Fontemaggi G, Cong YS, et al.. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. *Mol. Cell. Biol*. 2000;20:3764–71.

- [59] Cong, YS, Wen J, and Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. *Hum. Mol. Genet.* 1999;8:137–142.
- [60] Horikawa, I, Cable PL, Afshari C, and Barrett JC. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. *Cancer Res.* 1999;59:826–830.
- [61] Takakura, M, Kyo S, Kanaya T, Hirano H, Takeda J, et al.. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. *Cancer Res.* 1999;59:551–557.
- [62] Wright WE, M. Piatyszek A, Rainey WE, Byrd W, and Shay JW. Telomerase activity in human germline and embryonic tissues and cells. *Dev. Genet.* 1996;18:173–179.
- [63] Wick M, Zubov D, and Hagen G. Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). *Gene.* 1999;232:97–106.
- [64] Flores I, Benetti R and Blasco AM. Telomerase regulation and stem cell behavior. *Current Opinion in Cell Biology.* 2006;18:245-260.
- [65] Gellert GC, Jackson SR, Dikmen ZG, Wright WE, Shay JW. Telomerase as a therapeutic target in cancer. *ELSEVIER.* 2005;2(2):159-164.
- [66] Gardner LB, Lee LA, Dang CV. *c-myc* Protooncogene. 2nd ed. Elsevier Science (USA). p.556-559.



- [67] DANG CV. c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism. MOLECULAR AND CELLULAR BIOLOGY. 1999 Jan;19(1):1–11.
- [68] Natural Remedie Research Centre. Quality Control Department. *Zingiber officinale*,1-33. (Bangalore).
- [69] Shukla Y, Singh M. Cancer preventive properties of ginger: A brief review. Food and Chemical Toxicology. 2007;45:683–690.
- [70] Kumar KJ., Na HK, Surh YJ. Ginger-Derived Phenolic Substances with Cancer Preventive and Therapeutic Potential. Forum Nutr. 2009;61: 182–192.
- [71] Mustafa T, Srivastava KC, Jensen KB. Drug development report(9): pharmacology of ginger, *Zingiber officinale*. J. Drug Dev. 1993;6: 25–39.
- [72] Mascolo N, Jain R, Jain SC, Capasso F. Ethnopharmacologic investigation of ginger (*Zingiber officinale*). J. Ethnopharmacol. 1989;27:129–140.
- [73] Jeong CH, Bode AM, Pugliese A., et al.. 6-Gingerol suppresses colon cancer growth by targeting leukotriene A4 hydrolase. Cancer Res. 2009;69: 5584-91.
- [74] Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006;1:1112-16.
- [75] Szatmari I, Aradi J. Telomeric repeat amplification, without shortening or lengthening of the telomerase products: a method to analyze the processivity of telomerase enzyme. Nucleic Acids Res. 2001;29:E3.

- [76] Cristofari G, Reichenbach P, Regamey PO, et al.. Low- to high-throughput analysis of telomerase modulators with Telospot. *Nat Methods*. 2007;4:851-853.
- [77] Jolad SD, Lantz RC, Solyom AM, Chen GJ. et al.. Fresh organically grown ginger (*Zingiber officinale*): composition and effects on LPS-induced PGE2 production. *Phytochemistry*. 2004;65:1937-54.
- [78] Lee SH., Cekanova M., Baek SJ. Multiple mechanisms are involved in 6-gingerol-induced cell growth arrest and apoptosis in human colorectal cancer cells. *Mol Carcinog*. 2008;47:197-208.
- [79] Lee SH, Seo EY, Kang NE and Kim WK. 6-Gingerol inhibits metastasis of MDA-MB-231 human breast cancer cells. *J Nutr Biochem*. 2008;19: 313-319.
- [80] Hung JY, Hsu Y, Li CT, et al.. 6-Shogaol, an active constituent of dietary ginger, induces autophagy by inhibiting the AKT/mTOR pathway in human non-small cell lung cancer A549 cells. *J Agric Food Chem*. 2009;57:9809–16.
- [81] Kim JS, Lee SI, Park HW, et al.. Cytotoxic components from the dried rhizomes of *Zingiber officinale Roscoe*. *Arch Pharm Res*. 2008;31: 415-418.
- [82] Pan MH, Hsieh MC, Kuo JM, et al.. 6-Shogaol induces apoptosis in human colorectal carcinoma cells via ROS production, caspase activation, and GADD 153 expression. *Mol Nutr Food Res*. 2008;52:527-537.

- [83] Chung WY, Jung YJ, Surh YJ, Lee SS and Park KK. Antioxidative and antitumor promoting effects of 6-paradol and its homologs. *Mutat Res.* 2001;496:199-206.
- [84] Lee E, Surh YJ. Induction of apoptosis in HL-60 cells by pungent vanilloids, 6-gingerol and 6-paradol. *Cancer Lett.* 1998;134:163-168.
- [85] Keum YS, Kim J, Lee KH, et al.. Induction of apoptosis and caspase-3 activation by chemopreventive 6-paradol and structurally related compounds in KB cells. *Cancer Lett.* 2002;177:41-47.
- [86] Tuntiwechapikul W, Taka T, Songsomboon C, et al.. Ginger Extract Inhibits Human Telomerase Reverse Transcriptase and c-Myc Expression in A549 Lung Cancer Cells. *J Med Food.* 2010;13: 1347–54.
- [87] Armanios M, Greider CW. Telomerase and cancer stem cells. *Cold Spring Harb Symp Quant Biol.* 2005;70:205-208.
- [88] Soucek L, Whitfield J, Martins CP, et al.. Modelling Myc inhibition as a cancer therapy. *Nature.* 2008;455:679-683.
- [89] Robson S, Pelengaris S, Khan M. c-Myc and downstream targets in the pathogenesis and treatment of cancer. *Recent Pat Anticancer Drug Discov.* 2006;1:305-326.